CFDA Publishes Four Draft Guidances on Inspections of Generic Drug Development

Posted 06 February 2017 By Yingying Liu, Siegfried Schmitt

placeholder+image This article provides the details of four draft guidances published on 21 December 2016 by the China Food and Drug Administration (CFDA) regarding on-site inspection of generic drugs, including how CFDA will be evaluating their quality and efficacy and possible inspection outcomes and the responsibilities of 31 local province level FDA inspection teams in China.

Share this article:

Categories: Prescription drugs, Generic drugs, Clinical, Compliance, Features, China, CFDA

Tags: Draft Guidance

Regulatory Exchange: Latest Updates From the Community